JP2016512201A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512201A5 JP2016512201A5 JP2015561753A JP2015561753A JP2016512201A5 JP 2016512201 A5 JP2016512201 A5 JP 2016512201A5 JP 2015561753 A JP2015561753 A JP 2015561753A JP 2015561753 A JP2015561753 A JP 2015561753A JP 2016512201 A5 JP2016512201 A5 JP 2016512201A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- receptor antagonist
- induced
- eta receptor
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 239000002464 receptor antagonist Substances 0.000 claims 18
- 229940044551 receptor antagonist Drugs 0.000 claims 18
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 14
- 208000033626 Renal failure acute Diseases 0.000 claims 14
- 201000011040 acute kidney failure Diseases 0.000 claims 14
- 206010021143 Hypoxia Diseases 0.000 claims 10
- 230000007954 hypoxia Effects 0.000 claims 9
- 208000028867 ischemia Diseases 0.000 claims 7
- 208000017169 kidney disease Diseases 0.000 claims 7
- 206010061481 Renal injury Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 208000037806 kidney injury Diseases 0.000 claims 5
- 208000012998 acute renal failure Diseases 0.000 claims 4
- 238000005259 measurement Methods 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical group C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 claims 2
- 229950010993 atrasentan Drugs 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 102000013519 Lipocalin-2 Human genes 0.000 claims 1
- 108010051335 Lipocalin-2 Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010062104 Renal mass Diseases 0.000 claims 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 208000037978 tubular injury Diseases 0.000 claims 1
- 230000010024 tubular injury Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775174P | 2013-03-08 | 2013-03-08 | |
| US61/775,174 | 2013-03-08 | ||
| PCT/US2014/022688 WO2014138738A1 (en) | 2013-03-08 | 2014-03-10 | Methods of treating acute kidney injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512201A JP2016512201A (ja) | 2016-04-25 |
| JP2016512201A5 true JP2016512201A5 (enExample) | 2017-04-13 |
Family
ID=51492045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561753A Pending JP2016512201A (ja) | 2013-03-08 | 2014-03-10 | 急性腎障害の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160015701A1 (enExample) |
| EP (1) | EP2964671A4 (enExample) |
| JP (1) | JP2016512201A (enExample) |
| CN (1) | CN105324395A (enExample) |
| AU (1) | AU2014225320A1 (enExample) |
| BR (1) | BR112015020788A2 (enExample) |
| CA (1) | CA2901922A1 (enExample) |
| HK (1) | HK1220209A1 (enExample) |
| MX (1) | MX2015011730A (enExample) |
| WO (1) | WO2014138738A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014259961A1 (en) | 2013-04-30 | 2015-11-05 | Abbvie, Inc. | Methods for improving lipid profiles using atrasentan |
| WO2016073846A1 (en) * | 2014-11-07 | 2016-05-12 | Abbvie Inc. | Methods of treating ckd using predictors of fluid retention |
| EP3235496A1 (en) | 2016-04-19 | 2017-10-25 | Noorik Biopharmaceuticals AG | Treatment of acute renal failure |
| MA46459B1 (fr) * | 2016-10-05 | 2021-03-31 | Mitobridge Inc | Méthode de traitement de lésions rénales aiguës |
| KR102177349B1 (ko) * | 2018-02-13 | 2020-11-12 | 서울대학교병원 | 체세포 복제 효율 증진용 조성물 |
| US10978176B2 (en) | 2018-06-29 | 2021-04-13 | pulseData Inc. | Machine learning systems and methods for predicting risk of renal function decline |
| AU2020379649A1 (en) * | 2019-11-06 | 2022-05-26 | Mannin Research Inc. | Inhibition of the VE-PTP phosphatase protects the kidney from ischemia-reperfusion injury |
| US20220304979A1 (en) * | 2019-12-17 | 2022-09-29 | Chinook Therapeutics, Inc. | Methods of reducing disease flares |
| IL293921A (en) | 2019-12-17 | 2022-08-01 | Chinook Therapeutics Inc | Methods for treating iga kidney disease with atresantan |
| JP2023521169A (ja) * | 2020-04-10 | 2023-05-23 | チヌーク セラピューティクス，インコーポレイテッド | 糖尿病性腎疾患の処置方法 |
| CN113209111A (zh) * | 2021-05-14 | 2021-08-06 | 上海海糖生物医药科技有限公司 | 一种褐藻寡糖的应用 |
| CN115005157B (zh) * | 2022-06-02 | 2023-12-26 | 上海交通大学医学院附属新华医院 | 一种低氧致急性肾损伤动物模型的构建方法 |
| CN116731117B (zh) * | 2023-06-19 | 2024-05-10 | 武汉大学 | Kim-1靶向性多肽及其在急性肾损伤中肾靶向性的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273961A (en) * | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
| WO2005104702A2 (en) * | 2004-04-23 | 2005-11-10 | Renal Diagnostic, Inc. | An automated non- invasive real-time acute renal failure detection system |
| US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| US9255931B2 (en) * | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
-
2014
- 2014-03-10 HK HK16108216.3A patent/HK1220209A1/zh unknown
- 2014-03-10 BR BR112015020788A patent/BR112015020788A2/pt not_active IP Right Cessation
- 2014-03-10 WO PCT/US2014/022688 patent/WO2014138738A1/en not_active Ceased
- 2014-03-10 AU AU2014225320A patent/AU2014225320A1/en not_active Abandoned
- 2014-03-10 CN CN201480011012.2A patent/CN105324395A/zh active Pending
- 2014-03-10 US US14/772,621 patent/US20160015701A1/en not_active Abandoned
- 2014-03-10 EP EP14760019.1A patent/EP2964671A4/en not_active Withdrawn
- 2014-03-10 CA CA2901922A patent/CA2901922A1/en not_active Abandoned
- 2014-03-10 JP JP2015561753A patent/JP2016512201A/ja active Pending
- 2014-03-10 MX MX2015011730A patent/MX2015011730A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512201A5 (enExample) | ||
| Darras et al. | Dystrophinopathies | |
| Tan et al. | Dexmedetomidine protects against acute kidney injury through downregulating inflammatory reactions in endotoxemia rats | |
| McCullough et al. | Effects of intra-arterial and intravenous iso-osmolar contrast medium (iodixanol) on the risk of contrast-induced acute kidney injury: a meta-analysis | |
| JP2011184466A5 (enExample) | ||
| JP2016512201A (ja) | 急性腎障害の治療方法 | |
| JP2010256190A5 (enExample) | ||
| JP2017522270A5 (enExample) | ||
| Yap et al. | The clinical utility of CD163 in viral diseases | |
| Naeem et al. | Fenoldopam for the prevention of contrast-induced nephropathy (CIN)—do we need more trials? A meta-analysis | |
| deLemos et al. | Amoxicillin-clavulanate induced DILI: 113 cases from the US Drug-Induced Liver Injury Network (DILIN): 1050 | |
| JP2015049050A5 (enExample) | ||
| Lieberman | Objective measures of asthma control: sputum eosinophils, nitric oxide, and other inflammatory mediators | |
| Hubner et al. | Influence of co-morbidity on renal function assessment by Cockcroft–Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy | |
| JP2016080672A (ja) | 悪性リンパ腫の検出法 | |
| Dimitriadi et al. | Evaluation of the corrective effect of therapeutic plasmapheresis on the state of renal function in patients after surgical treatment of localized kidney cancer | |
| Lomborg et al. | Retroperitoneal fibrosis as the presenting manifestation of IgG4-related disease in a patient previously diagnosed with granulomatosis with polyangiitis (Wegener’s): one disease or two? | |
| Baudin et al. | 6564 POSTER correlation of PFS with early response of chromogranin A and 5-hydroxyindoleacetic acid levels in Pts with advanced neuroendocrine tumours: phase III RADIANT-2 study results | |
| Mahmoud et al. | Epidemiology and clinical outcome of ICU-acquired dysnatremia in critically ill medical patients, a single center study | |
| RU2015151533A (ru) | Способ прогнозирования клинического эффекта после операции реваскуляризации почек у больных с ишемической нефропатией | |
| Morfin et al. | Kidney Disorders | |
| Ahmed et al. | PTU-019 Methadone use is associated with the development of common bile duct dilatation among patients with hepatitis C: results of a retrospective cohort study | |
| Zanusso et al. | Effect of Hospital Pay for Performance on Mortality in England | |
| Harris et al. | PTU-133 Effect of Eluxadoline on Abdominal and Bowel Symptoms Over Time in Phase 3 Clinical Trials in Patients with Irritable Bowel Syndrome with Diarrhoea (IBS-D) | |
| Karslıoğlu | Observation of Glomerular Filtration Change in Chronic Hepatitis B Patients Using Tenofovir Disoproxil Fumarate. |